Role of integrase inhibitors in the treatment of HIV disease

References

• Fischl MA, Richman DD, Grieco MH et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med.317, 185–191 (1987).
   PubMed Web of Science ®Google Scholar
• Delta coordinating committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet348, 283–291 (1996).
   PubMed Web of Science ®Google Scholar
• Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med.337, 725–733 (1997).
   PubMed Web of Science ®Google Scholar
• Walensky RP, Paltiel AD, Losina E. The survival benefits of AIDS treatment in the United States. J. Infect. Dis.194, 11–19 (2006).
   PubMed Web of Science ®Google Scholar
• Vella S, Palmisano L. The global status of resistance to antiretroviral drugs. Clin. Infect. Dis.41(Suppl. 4), S239–S246 (2005).
   PubMed Web of Science ®Google Scholar
• Kitamura Y, Ayukawa T, Ishikawa T, Kanda T, Yoshiike K. Human endogenous retrovirus K10 encodes a functional integrase. J. Virol.70, 3302–3306 (1996).
   PubMed Web of Science ®Google Scholar
• Rice PA, Baker TA. Comparative architecture of transposases and integrase complexes. Nature Struct. Biol.8, 302–307 (2001).
   Google Scholar
• Jacque JM, Stevenson M. The innernuclear-envelope protein emerin regulates HIV-1 infectivity. Nature441, 641–645 (2006).
   PubMed Web of Science ®Google Scholar
• Liu H, Dow C E, Arora R et al. Integration of human immunodeficiency virus type 1 in untreated infection occurs preferentially within genes. J. Virol.80, 7765–7768 (2006).
   PubMed Web of Science ®Google Scholar
• Cara A, Reitz MS. New insight on the role of extrachromosomal retroviral DNA. Leukemia11, 1395–1398 (1997).
   PubMed Web of Science ®Google Scholar
• Sharkey ME, Teo L, Greenough T et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nat. Med.6, 76–81 (2000).
   PubMed Web of Science ®Google Scholar
• McDermott J L, Martini I, Ferrari D et al. Decay of human immunodeficiency virus type 1 unintegrated DNA containg two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia. J. Clin. Microbiol.43, 5272–5274 (2005).
   PubMed Web of Science ®Google Scholar
• Chu TK, Davies DR. Structure and function of HIV-1 integrase. Curr. Top. Med. Chem.4, 965–977 (2004).
   PubMed Web of Science ®Google Scholar
• Lu R, Limon A, Ghory HZ, Engelman A. Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase. J. Virol.79, 2493–2505 (2005).
   PubMed Web of Science ®Google Scholar
• Chow SA, Vincent KA, Elison V, Brown PO. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science255, 723–726 (1992).
   PubMed Web of Science ®Google Scholar
• Fesen MR, Kohn KW, Lefeurtre F, Pommier Y. Inhibitors of human immunodeficiency virus integrase. Proc. Nat. Acad. Sci. USA90, 2399–2403 (1993).
   PubMed Web of Science ®Google Scholar
• Craigie R, Mizuuchi K, Bushman FD, Engelman A. A rapid in vitro assay for HIV DNA integration. Nucleic Acids Res.19, 2729–2734 (1991).
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Hastings JC, Wolfe AL, Emini EA. A novel assay for the DNA strand-transfer reaction of HIV-1 integrase. Nucleic Acids Res.22, 1121–1122 (1994).
   PubMed Web of Science ®Google Scholar
• Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discovery4, 236–248 (2005).
   PubMed Web of Science ®Google Scholar
• Goldgur Y, Craigie R, Cohen GH et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl Acad. Sci. USA96, 13040–13043 (1999).
   PubMed Web of Science ®Google Scholar
• Hazuda D, Felock P, Wilmer M et al. Inhibitors of strand transfer that prevent integration and inhibit HIV replication in cells. Science287, 646–650 (2000).
   PubMed Web of Science ®Google Scholar
• Grobler JA, Stillmock K, Hu B et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl Acad. Sci. USA99, 6661–6666 (2002).
   PubMed Web of Science ®Google Scholar
• Fikkert V, Van Maele B, Vercammen J et al. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J. Virol.77, 11459–11470 (2003).
   PubMed Web of Science ®Google Scholar
• Hazuda D, Anthony NJ, Gomez RP et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. natil Acad. Sci. USA101, 11233–11238 (2004).
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Young SD, Guare JP et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science305, 528–532 (2004).
   PubMed Web of Science ®Google Scholar
• Embrey MW, Way JS, Funk TW et al. A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6] naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells. Bioorg. Med. Chem. Lett.15, 4550–4554 (2005).
   PubMed Web of Science ®Google Scholar
• Sato M, Motomura T, Aramaki H et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem.49, 1506–1508 (2006).
   PubMed Web of Science ®Google Scholar
• Billich A. S-1360 Shionogi-GlaxoSmithKline. Curr. Opin. Investig. Drugs4, 206–209 (2003).
   PubMedGoogle Scholar
• Mousnier A, Leh H, Nouscadet JF, Dergemont C. Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives. Mol. Pharmacol.66, 783–788 (2004).
   PubMed Web of Science ®Google Scholar
• Little S, Drusano C, Schooley R et al. Antiretroviral effect of L-000870810, a novel HIV-1 integrase inhibitor, in HIV-1-infected patients. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infection. MA, USA, February 22–25 Abstr. 161 (2005).
   Google Scholar
• Markowitz M, Morales-Ramirez JO, Nguyen B-J et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment- naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr.43, 509-515 (2006).
   Google Scholar
• Grinsztejn B, Nguyen BY, Katlama C et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inihibitor, in patients with triple-class resistant virus. Proceedings of the 13th Conference on Retroviruses and Opportunistic Infection. CO, USA February 5–8 Abstr. 159LB (2006).
   Google Scholar
• Grinsztejn B Nguyen BY, Katlama C et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple class resistant virus. Proceedings of the 46th ICAAC, CA, USA, September 27–30 , Abstr. H-1670b (2006).
   Google Scholar
• Markowitz M, Nguyen B-Y, Gotuzzo F et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment naive HIV-1 infected patients. Proceedings of the XVI International AIDS Conference, Toronto (Canada) August 13–18, Abstr. THLB0214 (2006).
   Google Scholar
• Iwamoto M, Wenning LA, Petry SA et al. Minimal effect of ritonavir (RTV) and efavirenz (EFV) on the pharmacokinetics (OK) of MK0–518. Proceedings of the 46th ICAAC, San Francisco (CA) September 27–30, Abstr. A-373 (2006).
   Google Scholar
• Wenning LA, Hanley H, Stone J et al. Effect of tipranavir + ritonavir (tpv + rtv) on pharmacokinetics of MK-0518. Proceedings of the 46th ICAAC, CA, USA, September 27–30, Abstr. A-374 (2006).
   Google Scholar
• Wenning LA, Friedman E Kost JT. Lack of a significant drug interaction between MK-0518 and tenofovir disoproxil fumarate (TDF). Proceedings of the 46th ICAAC, CA, USA September 27–30, Abstr. A-375 (2006)
   Google Scholar
• DeJesus E, Berger D, Markowitz M et al. Antiviral activity, pharmacokinetics, and dose response of the HIV integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr.43, 1–5 (2006).
   PubMed Web of Science ®Google Scholar
• Winston A, Hales G, Amin J et al. The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. AIDS19, 1393–1399 (2005).
   PubMed Web of Science ®Google Scholar
• Fikkert V, Hombrouck A, Van Remoortel B et al. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS18, 2019–2028 (2004).
   PubMed Web of Science ®Google Scholar
• Hazuda DJ and the MRL HIV-1 Drug Discovery Team. Context dependent effects of mutations associated with resistance to inhibitors of HIV-1 integrase strand transfer. Antiviral Ther.10, S82 (2005).
   Google Scholar
• Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antiviral Ther.11, S28 (2006).
   Web of Science ®Google Scholar
• Fransen S, Gupta S, Paxinos E et al. Natural variation in susceptibility of patient-derived HIV-1 to an integrase strand transfer inhibitor. Antiviral Ther.11, S27 (2006).
   Web of Science ®Google Scholar
• Di Santo R, Costi R, Roux A et al. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities and mechanism of actions. J. Med. Chem.49, 1939–1945 (2006).
   PubMed Web of Science ®Google Scholar
• Dupuis ML, Cianfriglia M, Costi R et al. HIV-1 Integrase Inhibitors Are Potent Sustrates for the MDR1 Multidrug Transporter. Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections. CO, USAFebruary 5–8 Abstr. 565 (2006).
   Google Scholar
• Tsibris AM, Kuritzkes DR. Chemokine antagonists as therapeutics: focus on HIV-1. Annu. Rev. Med.58, 445-459 (2007).
   PubMed Web of Science ®Google Scholar
• Siliciano JD, Siliciano RF. The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure. Curr. Opin. HIV AIDS1, 121–128 (2006).
   PubMed Web of Science ®Google Scholar